Silence Therapeutics (SLN) Receivables (2019 - 2025)

Silence Therapeutics has reported Receivables for 7 years, with the latest figure at $28000.0 in Q3 2025.

• Quarterly Receivables changed N/A year-over-year to $28000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28000.0 (changed N/A YoY) and the FY2024 annual result came in at $972000.0, up 243.48% from the prior year.
• Receivables declined to $28000.0 in Q3 2025 per SLN's latest filing, from $85000.0 in the prior quarter.
• Over five years, Receivables peaked at $1.1 million in Q4 2022 and troughed at $28000.0 in Q3 2025.
• A 5-year average of $418343.4 and a median of $282982.6 in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2021 and 2024: Receivables plunged 98.85% in 2021, then soared 243.48% in 2024.
• Over 5 years, Receivables stood at $446191.5 in 2021, then jumped by 140.53% to $1.1 million in 2022, then tumbled by 73.63% to $282982.6 in 2023, then jumped by 243.48% to $972000.0 in 2024, then tumbled by 97.12% to $28000.0 in 2025.
• According to Business Quant data, Receivables over the past three periods registered $28000.0, $85000.0, and $41000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.